Bexotegrast
CAS号 | 2376257-44-0 | 货号 | BCP49211 |
中文名 | Bexotegrast | ||
英文名 | Bexotegrast | ||
中文别名 | |||
英文别名 | PLN-74809;PLN 74809;PLN74809; | ||
分子式 | C27H36N6O3 | 分子量 | 492.61 |
生物活性 | Bexotegrast is a small-molecule that dually inhibits both αvβ6 and αvβ1 to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical development of this compound. Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries, and for participants with PSC (NCT04480840). In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome. | ||
信号通路 | Angiogenesis/Protein Tyrosine Kinase | ||
靶 点 | Integrin |
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服:
- 全国免费电话:400-099-8200
瀚香生物(Biochempartner) 的所有产品和服务仅用于科学研究,禁止用于人体和治疗!